SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
197 hedge funds and large institutions have $729M invested in SANGAMO THERAPEUTICS INC in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 52 increasing their positions, 77 reducing their positions, and 42 closing their positions.
7% more call options, than puts
Call options by funds: $21.9M | Put options by funds: $20.5M
0.91% less ownership
Funds ownership: 63.7% → 62.78% (-0.91%)
9% less funds holding
Funds holding: 217 → 197 (-20)
32% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 77
34% less capital invested
Capital invested by funds: $1.1B → $729M (-$368M)
43% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 42
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$16.8M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.9M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$11.4M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.06M |
| 3 |
Millennium Management
New York
|
-$7.88M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.48M |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$7.36M |
SGMO Hedge Fund Activity: Q4 2018 in Review
197 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2018, worth a combined $729M — down 34% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of SGMO and 24 opened new positions — a net loss of 18 holders — while 77 trimmed existing stakes and 52 added.
The largest buyer was BB Biotech, opening a new position worth an estimated $16.8M. The largest seller was Casdin Capital, cutting an estimated $11.4M.
- 197 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2018, down from 217 in Q3 2018.
- Funds reported $729M of SANGAMO THERAPEUTICS INC stock for Q4 2018, down 34% quarter-over-quarter.
- 24 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2018 and 42 closed out, a net change of -18 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2018 was BB Biotech, an estimated $16.8M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2018 was Casdin Capital, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2018.